Display options
Share it on

Nat Sci Sleep. 2014 May 02;6:57-63. doi: 10.2147/NSS.S53132. eCollection 2014.

Armodafinil-induced wakefulness in animals with ventrolateral preoptic lesions.

Nature and science of sleep

Ramalingam Vetrivelan, Clifford B Saper, Patrick M Fuller

Affiliations

  1. Department of Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA, USA.

PMID: 24833927 PMCID: PMC4014362 DOI: 10.2147/NSS.S53132

Abstract

Armodafinil is the pharmacologically active R-enantiomer of modafinil, a widely prescribed wake-promoting agent used to treat several sleep-related disorders including excessive daytime sleepiness associated with narcolepsy, shift work sleep disorder, and obstructive sleep apnea/hypopnea syndrome. Remarkably, however, the neuronal circuitry through which modafinil exerts its wake-promoting effects remains unresolved. In the present study, we sought to determine if the wake-promoting effects of armodafinil are mediated, at least in part, by inhibiting the sleep-promoting neurons of the ventrolateral preoptic (VLPO) nucleus. To do so, we measured changes in waking following intraperitoneal administration of armodafinil (200 mg/kg) or the psychostimulant methamphetamine (1 mg/kg) in rats with cell-body specific lesion of the VLPO. Rats with histologically confirmed lesions of the VLPO demonstrated a sustained increase in wakefulness at baseline, but the increase in wakefulness following administration of both armodafinil and methamphetamine was similar to that of intact animals. These data suggest that armodafinil increases wakefulness by mechanisms that extend beyond inhibition of VLPO neurons.

Keywords: EEG; methamphetamine; orexin-saporin; sleep

References

  1. Science. 2002 May 31;296(5573):1636-9 - PubMed
  2. Psychopharmacology (Berl). 2002 Jun;161(4):387-95 - PubMed
  3. Curr Med Res Opin. 2006 Apr;22(4):761-74 - PubMed
  4. J Neurosci. 2002 Nov 1;22(21):9320-30 - PubMed
  5. Expert Opin Investig Drugs. 1998 Jan;7(1):99-112 - PubMed
  6. J Neurosci. 2001 Mar 1;21(5):1787-94 - PubMed
  7. Neuropsychopharmacology. 2008 Jun;33(7):1477-502 - PubMed
  8. Sleep. 2004 Feb 1;27(1):19-25 - PubMed
  9. J Neurosci. 2000 Nov 15;20(22):8620-8 - PubMed
  10. Nat Neurosci. 2005 Nov;8(11):1481-9 - PubMed
  11. Brain Res. 2002 Jun 21;941(1-2):43-52 - PubMed
  12. Sleep. 2012 Nov 01;35(11):1511-20 - PubMed
  13. Eur J Pharmacol. 1990 May 3;180(1):49-58 - PubMed
  14. J Neurosci. 2008 Aug 20;28(34):8462-9 - PubMed
  15. Eur J Neurosci. 2008 Apr;27(7):1793-800 - PubMed
  16. J Neurosci. 2011 Jul 6;31(27):10067-75 - PubMed
  17. Neuroscience. 2005;132(4):1027-34 - PubMed
  18. Neuron. 2010 Dec 22;68(6):1023-42 - PubMed
  19. Sleep. 2004 Feb 1;27(1):11-2 - PubMed
  20. Brain Res. 1992 Sep 25;591(2):319-26 - PubMed
  21. J Neurosci. 2000 May 15;20(10):3830-42 - PubMed
  22. PLoS One. 2012;7(9):e45471 - PubMed
  23. Neuroscience. 2005;130(4):983-95 - PubMed
  24. Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14128-33 - PubMed
  25. Neurosci Lett. 1998 Jan 30;241(2-3):95-8 - PubMed
  26. Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5448-52 - PubMed
  27. Ann Clin Psychiatry. 2004 Apr-Jun;16(2):101-9 - PubMed
  28. Science. 1996 Jan 12;271(5246):216-9 - PubMed
  29. J Comp Neurol. 2011 Apr 1;519(5):933-56 - PubMed

Publication Types

Grant support